FOLH1 and neoplasm: In an attempt to prolong circulation in the blood and therewith, to increase the dose delivered to tumors and the tumor-to-kidney ratio, PSMA ligands have been structurally modified by adding albumin-binding moieties [123,132,145,146,147,148,149,150].